Barclays PLC Acquires New Shares in Pharvaris (NASDAQ:PHVS)

Barclays PLC acquired a new stake in Pharvaris (NASDAQ:PHVS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 5,700 shares of the company’s stock, valued at approximately $106,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after purchasing an additional 5,753 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Pharvaris in the 3rd quarter worth $57,000. Jane Street Group LLC acquired a new position in Pharvaris in the 3rd quarter worth $526,000. Sphera Funds Management LTD. boosted its stake in Pharvaris by 8.9% in the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock worth $8,136,000 after purchasing an additional 36,027 shares during the period. Finally, State Street Corp acquired a new position in Pharvaris in the 3rd quarter worth $1,000,000.

Pharvaris Trading Down 1.1 %

Shares of NASDAQ PHVS opened at $19.32 on Friday. The firm has a market cap of $1.01 billion, a PE ratio of -6.90 and a beta of -3.06. Pharvaris has a 1-year low of $15.21 and a 1-year high of $33.00. The company has a fifty day moving average price of $19.37 and a 200 day moving average price of $19.35.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.